Abstract
Calpains, calcium activated neutral proteases (CANP), and calpastatin (CAST), their specific inhibitor, are involved in the proteolysis of amyloid precursor protein (APP), which is thought to be abnormal in Alzheimer’s disease (AD). We studied the CANP/CAST system in erythrocytes of 14 clinically probable AD patients, 11 young and 14 old controls. CANP and CAST activities in the control subjects significantly correlated with increasing age; old controls showed a significant increase in CANP and CAST activities compared to young controls. Values of CANP and CAST activities in AD patients were similar to those of young controls. The physiological age-related increase in proteolysis seems to be lost in AD patients, and this could play a role in the pathogenesis of the disease. However, due to the overlap of results between patients and controls, we could not reliably differentiate the healthy from the disease state on the basis of erythrocytic CANP/CAST activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Selkoe D.J.: Biochemistry of Alzheimer’s disease. In: Siegel G.J. (Ed.), Basic Neurochemistry: Molecular, Cellular and Medical Aspects, ed. 5. Raven Press, New York, 1994, pp. 919–933.
Siman R., Card J.P., Davis L.G.: Proteolytic processing of beta-amyloid precursor by Calpain I. J. Neurosci. 10: 2400–2411, 1990.
Zimmermann U.J.P., Schlaepfer W.W.: Characterization of a brain calcium-activated proteases that degrades neurofilament proteins. Biochem. 21: 3977–3983, 1982.
Murachi T.: Calpain and calpastatin. Trends Biochem. Sci. 88: 167–169, 1983.
Melloni E., Pontremoli S.: The Calpains. Trends Neurosci. 12: 438–444, 1989.
Lynch G., Baudry M.: Brain spectrin, calpain and long-term changes in synaptic efficacy. Brain Res. Bull. 18: 809–815, 1987.
Del Cerro S., Larson J., Oliver M.W., Lynch G.: Development of hippocampal long-term potentiation is reduced by recently introduced calpain inhibitors. Brain Res. 530: 91–95, 1990.
Mantle D., Perry E.K.: Comparison of Ca2+-activated proteinase enzyme and endogenous inhibitor activity in brain tissue from normal and Alzheimer’s disease cases. J. Neurol. Sci. 102: 220–224, 1991.
Saito K.I., Elce J.S., Hamos J.E., Nixon R.A.: Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA 90: 2628–2632, 1993.
Nilsson E., Alafuzoff I., Blennow K., Blomgren K., Hall C.M., Jansson I., Karlsson I., Wallin A., Gottfries C.G., Karlsson J.O.: Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol. Aging 11: 425–431, 1990.
Karlsson J.O., Blennow K., Holmberg B., Janson I., Karlsson I., Nilsson E., Wallin A., Gottfries C.G.: Increased proteolytic activity in erythrocytes from patients with Alzheimer’s disease. Dementia 3: 200–204, 1992.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of health and human services task force on Alzheimer’s disease. Neurology 34: 939–944, 1984.
Pontremoli S., Melloni E., Salamino F., Sparatore B., Viotti P., Michetti M., Duzzi L., Bianchi G.: Decreased level of calpain inhibitor in red blood cells from Milan hypertensive rats. Biochem. Biophys. Res. Commun. 3: 1370–1375, 1986.
Kenessey A., Banay-Schwartz M., De Guzman T., Lajtha A.: Calpain II activity and calpastatin content in brain regions of 3- and 24-old rats. Neurochem. Res. 15: 243–249, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soldati, L., Alberoni, M., Bianchi, G. et al. Erythrocytic calpain-calpastatin system in Alzheimer’s disease. Aging Clin Exp Res 8, 106–108 (1996). https://doi.org/10.1007/BF03339563
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03339563